Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2847)	2/7/2001 4:18:00 PM
From: Ian@SI	Read Replies (1) of 52153

Thanks to Bernard, Richard and Peter for the additional insights. Bernard, Given the rest of the info you've provided on SCIO's pipeline, I trust that you're aware that Natrecor sNDA is already filed and that your reference is to the fact that the first filing was insufficient requiring the additional trial and supplemental... at least, that's the meaning I took from seeing the <g>. Fortunately I did my buying between $5 and $6 last year rather than while awaiting the FDA approval the first time around. Ian. re: As far as SCIO, to me another interesting part is the research collaboration with Lilly in Alzheimer’s disease and their announcement of their alliance with Quintiles for the commercialization of nesiritide (if they successfully complete the VMAC trial <g>)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next